Royalty Pharma (MEX:RPRXN) Shares Outstanding (EOP): 444 Mil (As of Mar. 2026)


MEX:RPRXN Royalty Pharma PLC MEX:RPRXN
72 GF Score
Price MXN775.06
GF Value MXN535.17
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Shares Outstanding (EOP)?

Royalty Pharma MEX:RPRXN 72 Shares Outstanding (EOP) is 444 Mil as of Mar. 2026. GuruFocus rates MEX:RPRXN with a GF Score™ of 72/100 and a GF Value™ of MXN535.17. The stock has 10 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Royalty Pharma's shares outstanding for the quarter that ended in Mar. 2026 was 444 Mil.

Royalty Pharma's quarterly shares outstanding increased from Dec. 2025 (429 Mil) to Mar. 2026 (444 Mil). It means Royalty Pharma issued new shares from Dec. 2025 to Mar. 2026 .

Royalty Pharma's annual shares outstanding declined from Dec. 2024 (446 Mil) to Dec. 2025 (429 Mil). It means Royalty Pharma bought back shares from Dec. 2024 to Dec. 2025 .


Royalty Pharma  (MEX:RPRXN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Royalty Pharma Shares Outstanding (EOP) Related Terms


Royalty Pharma Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Shares Outstanding (EOP) Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 432.96 443.17 446.69 445.99 428.67

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 425.59 432.29 429.03 428.67 443.63

MEX:RPRXN vs BNTX, INSM, ROIV: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Royalty Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Royalty Pharma Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Royalty Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Royalty Pharma's Shares Outstanding (EOP) falls into.


MEX:RPRXN
72GF Score
Royalty Pharma PLC MEX:RPRXN
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 444 Mil mean?
Royalty Pharma (MEX:RPRXN) has a Shares Outstanding (EOP) of 444 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Shares Outstanding (EOP) too high?
Royalty Pharma's current Shares Outstanding (EOP) is 444 Mil. Overall, Royalty Pharma has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Shares Outstanding (EOP) compare to BNTX and INSM?
Royalty Pharma's Shares Outstanding (EOP) of 444 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Shares Outstanding (EOP) is 444 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Royalty Pharma (MEX:RPRXN) has a current Shares Outstanding (EOP) of 444 Mil. The stock's GF Value™ is MXN535.17, compared to a current price of MXN775.06 — trading 44.8% above its estimated fair value. The current Shares Outstanding (EOP) is 444 Mil. Royalty Pharma's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Royalty Pharma (MEX:RPRXN), the current Shares Outstanding (EOP) is 444 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (MEX:RPRXN) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of MXN775.06 is trading 44.8% above its estimated GF Value™ of MXN535.17.

Key valuation signals for MEX:RPRXN:

  • Shares Outstanding (EOP): 444 Mil
  • GF Value™: MXN535.17 vs. price of MXN775.06 (44.8% above fair value)
  • GF Score™: 72/100 with 10 warning signs

No single metric tells the full story. See the MEX:RPRXN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Royalty Pharma Business Description

Other Exchanges RPRX:USARPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
72GF Score

Get the complete analysis for MEX:RPRXN

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN775.06
Price
MXN535.17
GF Value